Abstract:The scale of the humanitarian and economic impact of the COVID-19 pandemic provided insights into the landscape of vaccine development. The magnitude of the Coronavirus and its variants—over 260 million cases and more than five million deaths by early 2022—has called overdue attention to how we foster investment in the development of new vaccines against emerging pathogens. Vaccines serve both as cost-effective tools to prevent outbreaks of infectious diseases and as mechanisms to shorten their duration and lessen their socio-economic impact. Yet, absent a pandemic or other large-scale public health crisis, most types of vaccine research and development (R&D) remain largely untapped.This Article argues that ongoing legal and policy debates about the problem of incentivizing robust levels of vaccine innovation routinely fail to acknowledge the role that the tax system can play in this area. Historically, policymakers have attempted to promote investment in vaccine R&D through the use of traditional innovation levers. Of these traditional innovation mechanisms are intellectual property (“IP”) and non-IP policy tools that allocate proprietary price and reward successful R&D, respectively. Patents, grants, regulatory vouchers, and— to a lesser extent—prizes are the limited arsenal of innovation policies that incidentally also aim to instigate vaccine development. Much less attention, however, has been paid to the idiosyncratic hurdles of vaccine research and the role of fiscal policy in spurring investments in vaccine-specific R&D. To fill this gap, this Article develops a general normative theory: the market-based characteristics of fiscal incentives make them especially well-suited to encourage investment in vaccine innovation, thereby contributing to increasing preparedness. Alas, we demonstrate that current design of tax incentives drives research away from vaccine and towards more profitable mainstream discoveries. Yet, when designed properly, fiscal apparatuses can offer several unique advantages in the vaccine context: the ability to harness private market mechanisms ex ante to economize on resources, administrative costs, regulatory capture, and informational problems. Building on this analytical premise, this Article offers a novel framework for optimal fiscal policy that spurs investment in vaccine R&D in a more predictable and streamlined fashion, while lowering risk associated with the vaccine development processes. Additionally, we illustrate how fiscal policy can be used as an effective tool for equitable distribution of the cost of developing vaccines for emerging diseases, which to date has never been fully explored. While focused on the tax system, our proposed approach is illustrative of, and contributes to, the growing call for “innovation policy pluralism” as defined by Professors Hemel and Ouellette in their work on the synergistic combination of different types of incentives to innovation. Finally, our proposed fiscal policy offers a blueprint for possible interventions in other traditionally underfunded areas in pharmaceutical research.

The economic case for scaling up health research and development: Lessons from the COVID-19 pandemic

Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges

Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis

Designing Pull Funding For A COVID-19 Vaccine

Calculating the Costs and Benefits of Advance Preparations for Future Pandemics

Impact of the 100 days mission for vaccines on COVID-19: a mathematical modelling study

Comparing research and development, launch, and scale up timelines of 18 vaccines: lessons learnt from COVID-19 and implications for other infectious diseases

Tax Policy and Pharmaceutical Innovation

Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis

Supply Chains Create Global Benefits from Improved Vaccine Accessibility

Public Sector Contribution to Vaccine Research and Development

Equitable vaccine distribution promotes socioeconomic benefits globally

International Vaccine Allocation: An Optimization Framework

The Allocation of US$ 105 Billion in Global Funding for Infectious Disease Research between 2000 and 2017: An Analysis of Investments from Funders in the G20 Countries

Cost-effective proactive testing strategies during COVID-19 mass vaccination: A modelling study

US public investment in development of mRNA covid-19 vaccines: retrospective cohort study

An optimal mechanism to fund the development of vaccines against emerging epidemics

Economic evaluation for mass vaccination against COVID-19

Optimizing Vaccine Allocation Strategies in Pandemic Outbreaks: An Optimal Control Approach

Testing fractional doses of COVID-19 vaccines

Modeling Framework to Evaluate Vaccine Strategies against the COVID-19 Pandemic